| Cell line name |
VMM13 |
|---|
| Accession |
CVCL_ZV79 |
|---|
| Resource Identification Initiative |
To cite this cell line use: VMM13 (RRID:CVCL_ZV79) |
|---|
| HLA typing |
Source: PubMed=10752474
| Class I | | HLA-A | A*01,02 | | HLA-B | B*53 |
|
|---|
| Disease |
Melanoma (NCIt: C3224) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Sex of cell |
Sex unspecified |
|---|
| Age at sampling |
Age unspecified |
|---|
| Category |
Cancer cell line |
|---|
| Publications | PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162
Slingluff C.L. Jr., Colella T.A., Thompson L., Graham D.D., Skipper J.C.A., Caldwell J., Brinckerhoff L., Kittlesen D.J., Deacon D.H., Oei C., Harthun N.L., Huczko E.L., Hunt D.F., Darrow T.L., Engelhard V.H.
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Cancer Immunol. Immunother. 48:661-672(2000) |
|---|
| Cross-references |
|---|
| Encyclopedic resources |
Wikidata; Q98134531
|
|---|
| Entry history |
|---|
| Entry creation | 02-Jul-2020 |
|---|
| Last entry update | 21-Mar-2023 |
|---|
| Version number | 4 |
|---|
